Nanoparticles in medicine: Therapeutic applications and developments

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 5, 2008, Pages 761-769

  Zhang, L ^a   Gu, F X ^a   Chan, J M ^a   Wang, A Z ^b   Langer, R S ^a   Farokhzad, O C ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; APREPITANT; ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; ESTRADIOL; FENOFIBRATE; GLATIRAMER; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIPOSOME; MACROGOL; MORPHINE SULFATE; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGVISOMANT; POLYMER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEVELAMER; UNINDEXED DRUG; VERTEPORFIN; VINCRISTINE;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; INFLUENZA; KAPOSI SARCOMA; KIDNEY DISEASE; LIPID VESICLE; MENOPAUSAL SYNDROME; MULTIPLE SCLEROSIS; MYCOSIS; MYOPIA; NANOTECHNOLOGY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OCULAR HISTOPLASMOSIS; OVARY CANCER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTOZOAL INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; UNSPECIFIED SIDE EFFECT; VOMITING;

DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 42349094203     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100400     Document Type: Review

References (49)

1. Farokhzad, O.C. & Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58, 1456-1459 (2006).
2. Liu, Y., Miyoshi, H. & Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120, 2527-2537 (2007).
3. Brannon-Peppas, L. & Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649-1659 (2004).
4. Kawasaki, E.S. & Player, A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1, 101-109 (2005).
5. Emerich, D.F. & Thanos, C.G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target. 15, 163-183 (2007).
6. Groneberg, D.A., Giersig, M., Welte, T. & Pison, U. Nanoparticle-based diagnosis and therapy. Curr. Drug Targets 7, 643-648 (2006).
7. Wagner, V., Dullaart, A., Bock, A.-K. & Zweck, A. The emerging nanomedicine landscape. Nat. Biotech. 24, 1211-1217 (2006).
8. Zhang, L. & Granick, S. How to stabilize phospholipid liposome (using nanoparticles). Nano Lett. 6, 694-698 (2006).
9. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-159 (2005).
10. Moghimi, S.M. & Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42, 463-478 (2003).
11. Northfelt, D.W. et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 16, 2445-2451 (1998).
12. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688-701 (2006).
13. Tanaka, T., Shiramoto, S., Miyashita, M., Fujishima, Y. & Kaneo, Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277, 39-61 (2004).
14. Deguchi, J.-O. et al. Inflammation in atherosclerosis - visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 114, 55-62 (2006).
15. Davis, F.F. The origin of pegnology. Adv. Drug Deliv. Rev. 54, 457-458 (2002).
16. Harries, M., Ellis, P. & Harper, P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23, 7768-7771 (2005).
17. Woodle, M.C. Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug Deliv. Rev. 32, 139-152 (1998).
18. Sapra, P. & Allen, T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190-7194 (2002).
19. Simoes, S., Moreira, J.N., Fonseca, C., Duzgunes, N. & de Lima, M.C. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 56, 947-965 (2004).
20. Bissett, D. et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 91, 50-55 (2004).
21. Hoekstra, R. et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 11, 6908-6915 (2005).
22. Tiwari, S.B. & Amiji, M.M. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J. Nanosci. Nanotechnol. 6, 3215-3221 (2006).
23. McCarthy, T.D. et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2, 312-318 (2005).
24. Seiler, M.P. et al. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol. Ther. 15, 386-392 (2007).
25. Gu, F.X. et al. Targeted nanoparticles for cancer therapy. Nano Today 2, 14-21 (2007).
26. Fonseca, M.J., Jagtenberg, J.C., Haisma, H.J. & Storm, G. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm. Res. 20, 423-428 (2003).
27. Schnyder, A., Krahenbuhl, S., Drewe, J. & Huwyler, J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Target. 13, 325-335 (2005).
28. Kabanov, A.V., Batrakova, E.V. & Alakhov, V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 82, 189-212 (2002).
29. Wong, H.L., Rauth, A.M., Bendayan, R. & Wu, X.Y. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur. J. Pharm. Biopharm. 65, 300-308 (2007).
30. Arifin, D.R. & Palmer, A.F. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules 6, 2172-2181 (2005).
31. Farokhzad, O.C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103, 6315-6320 (2006).
32. Raffaghello, L., Zuccari, G., Carosio, R., Orienti, I. & Montaldo, P.G. In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4). Clin. Cancer Res. 12, 3485-3493 (2006).
33. Torchilin, V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16 (2007).
34. Zhang, L. et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2, 1268-1271 (2007).
35. Kukowska-Latallo, J.F. et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65, 5317-5324 (2005).
36. Bhadra, D., Bhadra, S. & Jain, N.K. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm. Res. 23, 623-633 (2006).
37. Dutta, T. et al. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 15, 89-98 (2007).
38. Morgan, M.T. et al. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 66, 11913-11921 (2006).
39. Wosikowski, K. et al. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin. Cancer Res. 9, 1917-1926 (2003).
40. Xie, Y.L., Lu, W. & Jiang, X.G. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav. Brain Res. 173, 76-84 (2006).
41. Chavanpatil, M.D., Khdair, A. & Panyam, J. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules. Pharm. Res. 24, 803-810 (2007).
42. Hyung Park, J. et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 27, 119-126 (2006).
43. Raja, K.S. et al. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4, 472-476 (2003).
44. Everts, M. et al. Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett. 6, 587-591 (2006).
45. Jordan, A. et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J. Neurooncol. 78, 7-14 (2006).
46. Jurgons, R. et al. Drug loaded magnetic nanoparticles for cancer therapy. J. Phys. Condens. Matter 18, S2893-S2902 (2006).
47. Hirsch, L.R. et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA 100, 13549-13554 (2003).
48. Roy, I. et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J. Am. Chem. Soc. 125, 7860-7865 (2003).
49. Huo, Q. et al. A new class of silica cross-linked micellar core-shell nanoparticles. J. Am. Chem. Soc. 128, 6447-6453 (2006).